DK0946151T3 - Doseringsform med stigende dosisfrigivelse - Google Patents

Doseringsform med stigende dosisfrigivelse

Info

Publication number
DK0946151T3
DK0946151T3 DK97947642T DK97947642T DK0946151T3 DK 0946151 T3 DK0946151 T3 DK 0946151T3 DK 97947642 T DK97947642 T DK 97947642T DK 97947642 T DK97947642 T DK 97947642T DK 0946151 T3 DK0946151 T3 DK 0946151T3
Authority
DK
Denmark
Prior art keywords
dosage form
increasing dose
dose release
release
increasing
Prior art date
Application number
DK97947642T
Other languages
Danish (da)
English (en)
Inventor
Lawrence G Hamel
Jeri D Wright
Padmaja Shivanand
Atul Devdatt Ayer
Andrew Lam
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26707551&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0946151(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alza Corp filed Critical Alza Corp
Application granted granted Critical
Publication of DK0946151T3 publication Critical patent/DK0946151T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK97947642T 1996-11-25 1997-11-12 Doseringsform med stigende dosisfrigivelse DK0946151T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3174196P 1996-11-25 1996-11-25
US96760697A 1997-11-10 1997-11-10

Publications (1)

Publication Number Publication Date
DK0946151T3 true DK0946151T3 (da) 2006-08-28

Family

ID=26707551

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97947642T DK0946151T3 (da) 1996-11-25 1997-11-12 Doseringsform med stigende dosisfrigivelse

Country Status (12)

Country Link
EP (1) EP0946151B1 (de)
JP (2) JP5173089B2 (de)
CN (2) CN100477986C (de)
AT (1) ATE325606T1 (de)
AU (1) AU5267698A (de)
CA (1) CA2265668C (de)
DE (1) DE69735848T2 (de)
DK (1) DK0946151T3 (de)
ES (1) ES2264173T3 (de)
HK (1) HK1021620A1 (de)
PT (1) PT946151E (de)
WO (1) WO1998023263A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440457B1 (en) 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US5922736A (en) 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US6486177B2 (en) 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
KR100827254B1 (ko) 1998-06-03 2008-05-07 알자 코포레이션 연장된 약물 치료를 제공하기 위한 방법 및 장치
US6673367B1 (en) * 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US7083808B2 (en) 1998-12-17 2006-08-01 Euro-Celtique S.A. Controlled/modified release oral methylphenidate formulations
US6127385A (en) * 1999-03-04 2000-10-03 Pharmaquest Limited Method of treating depression using l-threo-methylphenidate
US6395752B1 (en) * 1999-03-04 2002-05-28 Pharmaquest Limited Method of treating depression using 1-threo-methylphenidate
EP1414416A4 (de) 2001-07-10 2007-06-27 Teva Pharma Arzneimittelabgabesystem für die aufsteigende oder absteigende arzneimittelabgabe nullter ordnung oder biphasisch nullter ordnung
CN1620284B (zh) 2001-12-24 2010-04-28 特瓦制药工业有限公司 含有用粉末或粒状材料的压缩环状体包鞘的有效成分片芯的剂型,及其生产工艺和工具
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US7988993B2 (en) 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
WO2005030182A1 (en) * 2003-09-26 2005-04-07 Alza Corporation Controlled release formulations exhibiting an ascending rate of release
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
US20100151020A1 (en) 2008-12-16 2010-06-17 Vered Rosenberger Drug delivery system for zero order, zero order biphasic, ascending or descending drug delivery of methylphenidate
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
EP4011364B1 (de) 2011-03-23 2023-12-13 Ironshore Pharmaceuticals & Development, Inc. Verfahren und zusammensetzungen zur behandlung von aufmerksamkeitsdefizitsyndrom
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
CA2936746C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US5082668A (en) * 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
CA2007181C (en) * 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
US5024843A (en) * 1989-09-05 1991-06-18 Alza Corporation Oral hypoglycemic glipizide granulation
ZA915648B (en) * 1990-07-23 1992-05-27 Alza Corp Oral osmotic device for delivering nicotine
US5156850A (en) * 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
US5166145A (en) * 1990-09-10 1992-11-24 Alza Corporation Antiemetic therapy
US5208037A (en) * 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
EP0664118B1 (de) * 1991-10-04 1999-08-25 Yoshitomi Pharmaceutical Industries, Ltd. Tablette mit verzögerter freisetzung
US5532003A (en) * 1994-01-18 1996-07-02 Alza Corporation Pentoxifylline therapy
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US5698224A (en) * 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
US5614578A (en) * 1994-10-28 1997-03-25 Alza Corporation Injection-molded dosage form
ATE234602T1 (de) * 1996-08-16 2003-04-15 Alza Corp Verabreichungsform zur abgabe von steigenden wirkstoffdosen

Also Published As

Publication number Publication date
CN100477986C (zh) 2009-04-15
PT946151E (pt) 2006-07-31
ATE325606T1 (de) 2006-06-15
DE69735848T2 (de) 2006-12-28
JP5173089B2 (ja) 2013-03-27
CA2265668A1 (en) 1998-06-04
EP0946151B1 (de) 2006-05-10
CA2265668C (en) 2005-08-23
WO1998023263A1 (en) 1998-06-04
AU5267698A (en) 1998-06-22
JP5215347B2 (ja) 2013-06-19
HK1021620A1 (en) 2000-06-23
CN1233953A (zh) 1999-11-03
JP2002513392A (ja) 2002-05-08
CN1636552A (zh) 2005-07-13
JP2010215632A (ja) 2010-09-30
CN1182839C (zh) 2005-01-05
ES2264173T3 (es) 2006-12-16
DE69735848D1 (de) 2006-06-14
EP0946151A1 (de) 1999-10-06

Similar Documents

Publication Publication Date Title
DK0946151T3 (da) Doseringsform med stigende dosisfrigivelse
HK1127997A1 (en) Dosage form and method for administering drug
PT957899E (pt) Forma de dosagem para proporcionar um medicamento numa dose crescente
PT1035834E (pt) Forma de dosagem osmotica que compreende primeiro e segundo revestimentos
ATE165000T1 (de) Dosierungsform zur verzoegerten wirkstofffreisetzung
NO972780D0 (no) Inhalasjonsanordning, fremgangsmåte for fordeling av et farmasöytisk aktivt stoff og fremgangsmåte for administrering av en dose med et farmasöytisk aktivt stoff
DK0663825T3 (da) Anvendelse af melatonin i orale doser til fremkaldelse af søvn
DE1001772T1 (de) Verbesserte verabreichungstechnik für multiple medikamentengaben
NZ508526A (en) Opioid formulations for treating pain
NO20006007L (no) Fremgangsmåte til dosering av et medikament, samt doseringsform
GEP20022783B (en) Method of Preventing and Delaying Onset of Alzheimer's Disease and Composition Therefor
NO305581B1 (no) Anvendelse av et benaktivt fosfonat i kombinasjon med et °strogenhormon, og preparat i enhetsdoseform for behandling av osteoporose
DK0998287T3 (da) Anvendelse af levobupivacain
ATE284206T1 (de) Transdermal verabreichtes dextromethorphan als hustenmittel
SE9101341D0 (sv) New medicinal use
SE9904424D0 (sv) Use of interleukin-6 in combination with leptin in treatment of obesity
PL328924A1 (en) Method of treating abuse of substances
ZA977873B (en) Dosage form and method for administering drug.
UA10754A (uk) Спосіб лікуваhhя артеріальhих гіпертеhзій різhого геhезу
HK1056117A1 (en) Treatment of hepatitis C with thymosin and pegylated interferon